Sangamo Therapeutics Inc (NASDAQ:SGMO) CFO Kathy Yi sold 5,000 shares of the business’s stock in a transaction dated Monday, October 15th. The stock was sold at an average price of $13.97, for a total value of $69,850.00. Following the completion of the transaction, the chief financial officer now owns 12,250 shares in the company, valued at approximately $171,132.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Kathy Yi also recently made the following trade(s):

  • On Monday, September 17th, Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock. The stock was sold at an average price of $14.66, for a total value of $73,300.00.
  • On Thursday, August 16th, Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock. The stock was sold at an average price of $15.39, for a total value of $76,950.00.

Shares of Sangamo Therapeutics stock opened at $14.79 on Wednesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 7.24 and a quick ratio of 7.24. The stock has a market capitalization of $1.72 billion, a P/E ratio of -21.13 and a beta of 2.97. Sangamo Therapeutics Inc has a fifty-two week low of $11.30 and a fifty-two week high of $27.50.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.02). The firm had revenue of $21.42 million during the quarter, compared to the consensus estimate of $21.43 million. Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. The firm’s quarterly revenue was up 159.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.17) earnings per share. Equities research analysts anticipate that Sangamo Therapeutics Inc will post -0.69 earnings per share for the current fiscal year.

Several research analysts recently commented on the company. BidaskClub upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, September 5th. Bank of America assumed coverage on Sangamo Therapeutics in a research note on Wednesday, June 20th. They issued a “buy” rating and a $24.00 price target on the stock. Zacks Investment Research upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 14th. Wedbush reiterated a “hold” rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research note on Thursday, August 9th. Finally, ValuEngine cut Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, September 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $21.00.

Institutional investors have recently made changes to their positions in the stock. Riverhead Capital Management LLC increased its holdings in Sangamo Therapeutics by 218.0% in the second quarter. Riverhead Capital Management LLC now owns 8,267 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 5,667 shares during the last quarter. Mount Yale Investment Advisors LLC increased its holdings in Sangamo Therapeutics by 2,202.8% in the second quarter. Mount Yale Investment Advisors LLC now owns 8,359 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 7,996 shares during the last quarter. NumerixS Investment Technologies Inc bought a new stake in Sangamo Therapeutics in the second quarter valued at about $125,000. Tyers Asset Management LLC increased its holdings in Sangamo Therapeutics by 301.3% in the second quarter. Tyers Asset Management LLC now owns 9,632 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 7,232 shares during the last quarter. Finally, Quantitative Systematic Strategies LLC bought a new stake in Sangamo Therapeutics in the second quarter valued at about $155,000. 63.84% of the stock is owned by hedge funds and other institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Recommended Story: Price to Earnings Ratio (PE), For Valuing Stocks

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.